top of page

Takeda and Affilogic partner to develop CNS therapies

Takeda Pharmaceutical Company and Affilogic have entered into a research collaboration to explore using Affilogic’s Nanofitins platform in therapies targeting the central nervous system (CNS).

Specifically, Affilogic and Takeda, through its research center in San Diego, California, will leverage their respective competencies to validate and optimize Nanofitins® that enable Takeda to deliver biotherapeutic candidates into the brain to address neurological disorders.

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page